載入...
In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
Activation of the ERK1/2 mitogen-activated protein kinases (MAPKs) confers resistance to the RAF inhibitors vemurafenib and dabrafenib in mutant BRAF-driven melanomas. Methods to understand how resistance develops are important to optimize the clinical utility of RAF inhibitors in patients. Here we...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3851924/ https://ncbi.nlm.nih.gov/pubmed/24121492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1628 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|